imatinib mesylate has been researched along with Conjunctival Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| do Carmo, LL; Mendonça, LG; Yung, AA | 1 |
| Cao, L; Chen, H; Jin, J | 1 |
| Artoni, A; Colombi, M; Deliliers, GL; Iurlo, A; Radaelli, F; Reda, G; Ripamonti, F; Vener, C | 1 |
3 other study(ies) available for imatinib mesylate and Conjunctival Diseases
| Article | Year |
|---|---|
Imatinib-Related Conjunctival Pigmentation.
Topics: Aged; Antineoplastic Agents; Conjunctival Diseases; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pigmentation Disorders | 2018 |
Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Conjunctival Diseases; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
Conjunctival hemorrhagic events associated with imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Conjunctival Diseases; Drug Hypersensitivity; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2007 |